ATE542802T1 - Hiv-inhibierende 5-substituierte pyrimidine - Google Patents

Hiv-inhibierende 5-substituierte pyrimidine

Info

Publication number: ATE542802T1
Authority: AT; Austria
Prior art keywords: hiv; inhibiting; substituted pyrimidines; pyrimidines; substituted
Prior art date: 2004-09-30

Application number

AT05789686T

Other languages

English (en)

Inventor

Jerome Guillemont

Jan Heeres

Paulus Joannes Lewi

Original Assignee

Tibotec Pharm Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-30

Filing date

2005-09-29

Publication date

2012-02-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE542802(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-29 Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd

2012-02-15 Application granted granted Critical

2012-02-15 Publication of ATE542802T1 publication Critical patent/ATE542802T1/de

Links

150000003230 pyrimidines Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Virology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT05789686T 2004-09-30 2005-09-29 Hiv-inhibierende 5-substituierte pyrimidine ATE542802T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04104805		2004-09-30
PCT/EP2005/054932 WO2006035069A1 (en)	2004-09-30	2005-09-29	Hiv inhibiting 5-substituted pyrimidines

Publications (1)

Publication Number	Publication Date
ATE542802T1 true ATE542802T1 (de)	2012-02-15

Family

ID=34929637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05789686T ATE542802T1 (de)	2004-09-30	2005-09-29	Hiv-inhibierende 5-substituierte pyrimidine

Country Status (17)

Country	Link
US (1)	US8946248B2 (de)
EP (1)	EP1797047B1 (de)
JP (1)	JP5046943B2 (de)
KR (1)	KR20070057837A (de)
CN (1)	CN101027288B (de)
AR (1)	AR051315A1 (de)
AT (1)	ATE542802T1 (de)
AU (1)	AU2005288866B2 (de)
BR (1)	BRPI0516748B8 (de)
CA (1)	CA2575472C (de)
ES (1)	ES2380631T3 (de)
IL (1)	IL181056A (de)
MX (1)	MX2007003796A (de)
RU (1)	RU2410379C2 (de)
TW (1)	TW200626561A (de)
WO (1)	WO2006035069A1 (de)
ZA (1)	ZA200702656B (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE542802T1 (de)	2004-09-30	2012-02-15	Tibotec Pharm Ltd	Hiv-inhibierende 5-substituierte pyrimidine
US8575342B2 (en) *	2004-09-30	2013-11-05	Tibotech Pharmaceuticals Ltd.	HIV inhibiting 5-heterocyclyl pyrimidines
US7935711B2 (en) *	2005-02-18	2011-05-03	Tibotec Pharmaceuticals Ltd.	HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
AU2007233737B2 (en) *	2006-03-30	2012-11-29	Janssen Sciences Ireland Uc	HIV inhibiting 5-amido substituted pyrimidines
US8318736B2 (en) *	2006-12-29	2012-11-27	Janssen R&D Ireland	HIV inhibiting 5,6-substituted pyrimidines
US9006243B2 (en) *	2006-12-29	2015-04-14	Janssen R&D Ireland	HIV inhibiting 6-substituted pyrimidines
TWI548621B (zh)	2011-04-22	2016-09-11	標誌製藥公司	經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
EP2872492B1 (de) *	2012-07-12	2018-01-31	Hetero Research Foundation	Verfahren zur herstellung von rilpivirin über ein neues zwischenprodukt
CA2890935A1 (en) *	2012-11-08	2014-05-15	Bristol-Myers Squibb Company	Alkyl amide-substituted pyrimidine compounds useful in the modulation of il-12, il-23 and/or ifn.alpha.
NZ715903A (en)	2014-01-30	2017-06-30	Signal Pharm Llc	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
EP3712134B1 (de)	2014-12-16	2023-11-29	Signal Pharmaceuticals, LLC	Salze von 2-(tert-butylamino)-4-((1r, 3r, 4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidin-5-carboxamid
US9513297B2 (en)	2014-12-16	2016-12-06	Signal Pharmaceuticals, Llc	Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (de)	2015-01-29	2024-11-20	Signal Pharmaceuticals, LLC	Isotopologe von 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidin-5-carboxamid
EP3325432B1 (de)	2015-07-24	2020-09-02	Celgene Corporation	Verfahren zur synthese von (1r, 2r, 5r)-5-amino-2-methylcyclohexanolhydrochlorid und nützliche zwischenprodukte darin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3459731A (en)	1966-12-16	1969-08-05	Corn Products Co	Cyclodextrin polyethers and their production
EP0310550B1 (de) *	1987-09-28	1993-05-26	Ciba-Geigy Ag	Schädlingsbekämpfungsmittel
CZ154398A3 (cs)	1995-11-23	1998-08-12	Janssen Pharmaceutica N.V.	Pevné směsi cyklodextrinů připravené vytlačováním taveniny
NO311614B1 (no)	1996-10-01	2001-12-17	Janssen Pharmaceutica Nv	Substituerte diamino-1,3,5-triazinderivater
NZ506679A (en)	1998-03-27	2002-11-26	Janssen Pharmaceutica Nv	HIV inhibiting pyrimidine derivatives
EP0945447A1 (de)	1998-03-27	1999-09-29	Janssen Pharmaceutica N.V.	Trisubstituierte 1,3,5-Triazinderivate zur Behandlung von HIV Infektionen
ID28376A (id) *	1998-11-10	2001-05-17	Janssen Pharmaceutica Nv	Pirimidina yang menghambat replikasi hiv
GB9828511D0 (en)	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
CA2406562C (en)	2000-05-08	2009-09-15	Janssen Pharmaceutica N.V.	Hiv replication inhibiting pyrimidines and triazines
BR0116493A (pt)	2000-12-21	2003-09-30	Vertex Pharma	Compostos de pirazol úteis como inibidores de proteìna cinase
JO3429B1 (ar) *	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
MXPA05005146A (es)	2002-11-15	2005-07-22	Tibotec Pharm Ltd	Indolpiridinio sustituido como compuestos antiinfecciosos.
US7504396B2 (en)	2003-06-24	2009-03-17	Amgen Inc.	Substituted heterocyclic compounds and methods of use
US8575342B2 (en)	2004-09-30	2013-11-05	Tibotech Pharmaceuticals Ltd.	HIV inhibiting 5-heterocyclyl pyrimidines
ATE520672T1 (de)	2004-09-30	2011-09-15	Tibotec Pharm Ltd	Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ATE542802T1 (de)	2004-09-30	2012-02-15	Tibotec Pharm Ltd	Hiv-inhibierende 5-substituierte pyrimidine
AU2007233737B2 (en)	2006-03-30	2012-11-29	Janssen Sciences Ireland Uc	HIV inhibiting 5-amido substituted pyrimidines
US8318736B2 (en)	2006-12-29	2012-11-27	Janssen R&D Ireland	HIV inhibiting 5,6-substituted pyrimidines
US9006243B2 (en)	2006-12-29	2015-04-14	Janssen R&D Ireland	HIV inhibiting 6-substituted pyrimidines

2005
- 2005-09-29 AT AT05789686T patent/ATE542802T1/de active
- 2005-09-29 TW TW094134108A patent/TW200626561A/zh unknown
- 2005-09-29 MX MX2007003796A patent/MX2007003796A/es active IP Right Grant
- 2005-09-29 KR KR1020077006048A patent/KR20070057837A/ko not_active Ceased
- 2005-09-29 CA CA2575472A patent/CA2575472C/en not_active Expired - Fee Related
- 2005-09-29 ES ES05789686T patent/ES2380631T3/es active Active
- 2005-09-29 EP EP05789686A patent/EP1797047B1/de not_active Expired - Lifetime
- 2005-09-29 WO PCT/EP2005/054932 patent/WO2006035069A1/en not_active Ceased
- 2005-09-29 BR BRPI0516748A patent/BRPI0516748B8/pt not_active IP Right Cessation
- 2005-09-29 JP JP2007534028A patent/JP5046943B2/ja not_active Expired - Fee Related
- 2005-09-29 CN CN2005800325534A patent/CN101027288B/zh not_active Expired - Fee Related
- 2005-09-29 AU AU2005288866A patent/AU2005288866B2/en not_active Ceased
- 2005-09-29 US US11/576,315 patent/US8946248B2/en not_active Expired - Fee Related
- 2005-09-29 RU RU2007116172/04A patent/RU2410379C2/ru active
- 2005-09-30 AR ARP050104155A patent/AR051315A1/es not_active Application Discontinuation
2007
- 2007-01-30 IL IL181056A patent/IL181056A/en active IP Right Grant
- 2007-03-29 ZA ZA200702656A patent/ZA200702656B/xx unknown

Also Published As

Publication number	Publication date
BRPI0516748B1 (pt)	2019-11-19
JP5046943B2 (ja)	2012-10-10
ES2380631T3 (es)	2012-05-17
AR051315A1 (es)	2007-01-03
RU2410379C2 (ru)	2011-01-27
BRPI0516748B8 (pt)	2021-05-25
WO2006035069A1 (en)	2006-04-06
CN101027288B (zh)	2013-04-17
IL181056A0 (en)	2007-07-04
CA2575472C (en)	2013-07-30
US8946248B2 (en)	2015-02-03
RU2007116172A (ru)	2008-11-10
TW200626561A (en)	2006-08-01
US20080262007A1 (en)	2008-10-23
CA2575472A1 (en)	2006-04-06
BRPI0516748A (pt)	2008-09-23
JP2008514681A (ja)	2008-05-08
KR20070057837A (ko)	2007-06-07
AU2005288866A1 (en)	2006-04-06
EP1797047B1 (de)	2012-01-25
ZA200702656B (en)	2008-08-27
IL181056A (en)	2014-02-27
CN101027288A (zh)	2007-08-29
AU2005288866B2 (en)	2012-07-26
EP1797047A1 (de)	2007-06-20
MX2007003796A (es)	2007-04-25

Publication	Publication Date	Title
ATE520672T1 (de)	2011-09-15	Hiv-hemmende 5-carbo- oder heterozyklisch substituierte pyrimidine
ATE529412T1 (de)	2011-11-15	Herbizide pyrimidine
EP1724267A4 (de)	2009-04-22	Pyrimidinderivat
EP1890703A4 (de)	2010-11-03	Pyrimidinverbindungen
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
MA28824B1 (fr)	2007-08-01	Derives de pyrimidine
EP1546115A4 (de)	2010-08-04	Substituierte pyrimidine
MA28813B1 (fr)	2007-08-01	Derives de pyrimidine
NO20044374L (no)	2004-10-14	Pyrimidinderivater
GB0415364D0 (en)	2004-08-11	Pyrimidine derivatives
EP1968950A4 (de)	2010-04-28	Pyrimidinkinaseinhibitoren
ZA200702656B (en)	2008-08-27	HIV inhibiting 5-substituted pyrimidines
ATE538130T1 (de)	2012-01-15	Pyrimidinderivate und ihre verwendung als p2y12- rezeptorantagonisten
GB0415367D0 (en)	2004-08-11	Pyrimidine derivatives
ATE509011T1 (de)	2011-05-15	Pyrimidinderivate als 11beta-hsd1-inhibitoren
ATE487718T1 (de)	2010-11-15	Substituierte bizyklische pyrimidonderivate
ATE420646T1 (de)	2009-01-15	Aminopyrimidine als kinase-modulatoren
ATE366242T1 (de)	2007-07-15	5-substituierte chinazolinonderivate
ATE350370T1 (de)	2007-01-15	2-substituierte pyrimidine
DE112005002826A5 (de)	2007-12-27	Ausgleichseinheit
DE602005004472D1 (de)	2008-03-13	Ausgleichsanordnung
DE602005010598D1 (de)	2008-12-04	Acrylsolzusammensetzung
IL172845A0 (en)	2006-06-11	2-substituted pyrimidines
ITVI20040274A1 (it)	2005-03-01	Distributore-dosatore di asfalto
AT6947U3 (de)	2005-03-25	Bob